More particularly, the present invention relates to novel chimeric compounds which are conjugates of reversible or irreversible cholinergic up-regulators and non-steroidal anti-inflammatory drugs (NSAIDs) and their use in the treatment of various CNS disorders and diseases such as Alzheimer's disease (AD), cerebral ischemia or stroke and closed head injury. [0003] The development of new drugs for